本文利用中国医药制造业企业2000~2015年省际面板数据,采用Hansen提出的“门槛回归模型”,测算政府科技资助与企业R D投入之间最优资助区间或强度。首先,利用系统广义矩估计法(SYS-GMM)对政府科技资助与企业R D投入之间的有效性进行检验。然后,通过门槛效应模型研究两者的非线性关系。并针对分析结果对各省份政府科技资助强度进行分析并提出建议。结果显示：政府科技资助与企业R D投入之间不仅存在显著促进作用,还存在门槛效应。最优资助强度(政府科技资助与R D投入比)为8.1%,随政府科技资助强度的增大,企业R D投入呈现先增大再变小的趋势,当政府科技资助强度超过19.6%,则为显著负相关,总体呈倒“U”型。

In this paper, we use the "threshold regression model" proposed by Hansen to estimate the optimal funding range between government subsidy and R D investment of pharmaceutical enterprises by using the provincial panel data of China"s pharmaceutical manufacturing industry from 2000 to 2015. Firstly, the System-GMM generalized moment estimation method is used to test the effectiveness of government subsidy for R D investment in pharmaceutical enterprises. Then, the nonlinear relationship between them by the threshold effect. Analyzes and puts forward some suggestions on the government subsidy intensity of each province. The results show that there is not only a significant relationship between government subsidy and R D investment in pharmaceutical enterprises, but also the threshold effect. The optimal funding range is within 8.1%, and the optimal funding rate is 8.1%. With the increase of government subsidy intensity, the R D investment of pharmaceutical enterprises is increasing first and then decreasing. When the government subsidy is more than 19.6% Significant negative correlation, the overall presentation of inverted "U"..

F270 R95

科技部“十二五”重大新药创制国家科技重大专项“辽宁省国家重大新药创制综合平台—基于信息管理的新药研发风险控制技术”资助项目( 2013ZX09301305)